Research

Mixed

A structured, telehealth-based Individualized Virtual Integrative Medicine (IVIM) protocol combined with semaglutide (branded or compounded) significantly enhances weight loss outcomes, achieving an average 19.5% total body weight reduction at 52 weeks.

If you have obesity and are using semaglutide, sticking to a structured care plan that includes regular medical check-ins, coaching, and app-based tracking can lead to significant weight loss (approx. 20% over a year). This holds true whether you use the branded version or a compounded version, provided you maintain continuous therapy without gaps. The key is adherence and managing side effects through professional support.

ModerateSupportsMEDIUM confidence
Patients with obesity completing 52 weeks of the IVIM clinical protocol on semaglutide lost 19.5 % of total body weight with 47.8 % of patients losing 20 % or more.
Jessica Duncan et al. · Obesity Pillars · 2025

Why this rating

Retrospective observational study with self-reported data and significant selection bias (exclusion of non-responders and those with gaps in therapy).

Source

Individualized virtual integrative medicine (IVIM): A clinical model for enhanced GLP-1 therapeutic outcomes

Jessica Duncan et al. · Obesity Pillars · 2025

DOI 10.1016/j.obpill.2025.100188

cohort · n=1131Cited 3×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →